Partnering Services
Meda's Hybrid-Naiioeiigiiieeriiig™ drug delivery platform generates more commercial opportunities than we can pursue independently. Strategic partnering is thereforea critical component of our ability to advance Meda's novel therapeutics programs into clinical developmentand onto the market.
Details
Meda'sobjective is to selectively partner at strategic stages of the development process while retainingselect therapeutic programs to develop independently. We wantto strategically integrate our patented technology platform into the best possible companies to insure we achieve the most rapid development of therapeutics which utilize our base technology. This strategy will enable the Company to maximize the number of lead compounds it can rapidly put into development as it continues to harvest output and develop its platform to a higher degree of productivity. Meda pursues the following types of collaborations: Licensing and/or co-development arrangements for our clinical pipeline products and preclinical drugs in development. Mcda can collaborate to develop therapeutics from our existing programs of both proteins/peptidesand small molecules. Partners may choose to advance these programs independently or in conjunction with Mcda. Meda can take the newly developed moleculesor existing patentexpired drugs and putthem in our platform to develop next generation of same drug to extent the further life the expired patented drug.
Customer reviews
No reviews were found for Partnering Services. Be the first to review!